130 related articles for article (PubMed ID: 36318800)
21. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
22. Study on early diagnosis of epithelial ovarian cancer by analysis of plasma septin-9 and clusterin level.
Lyu N; Wang Y; Wang J; Zhang Z; Kong W
J Cancer Res Ther; 2018 Jun; 14(Supplement):S444-S449. PubMed ID: 29970704
[TBL] [Abstract][Full Text] [Related]
23. Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM
Akhter MZ; Sharawat SK; Kumar V; Kochat V; Equbal Z; Ramakrishnan M; Kumar U; Mathur S; Kumar L; Mukhopadhyay A
Oncogene; 2018 Apr; 37(16):2089-2103. PubMed ID: 29379166
[TBL] [Abstract][Full Text] [Related]
24. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.
Wu X; Li D; Liu L; Liu B; Liang H; Yang B
Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956
[TBL] [Abstract][Full Text] [Related]
25. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
[TBL] [Abstract][Full Text] [Related]
26. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
27. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
28. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
29. [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2007 Dec; 42(12):834-9. PubMed ID: 18476518
[TBL] [Abstract][Full Text] [Related]
30. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
31. The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
Dis Markers; 2014; 2014():238197. PubMed ID: 25183900
[TBL] [Abstract][Full Text] [Related]
32. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer.
Wang B; Yu L; Yang GZ; Luo X; Huang L
Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients.
Bastani A; Asghary A; Heidari MH; Karimi-Busheri F
Eur J Gynaecol Oncol; 2017; 38(3):418-424. PubMed ID: 29693884
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.
Obermayr E; Castillo-Tong DC; Pils D; Speiser P; Braicu I; Van Gorp T; Mahner S; Sehouli J; Vergote I; Zeillinger R
Gynecol Oncol; 2013 Jan; 128(1):15-21. PubMed ID: 23017820
[TBL] [Abstract][Full Text] [Related]
35. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
36. Clinical implication of the serum galectin-1 expression in epithelial ovarian cancer patients.
Chen L; Yao Y; Sun L; Zhou J; Liu J; Wang J; Li J; Tang J
J Ovarian Res; 2015 Nov; 8():78. PubMed ID: 26589590
[TBL] [Abstract][Full Text] [Related]
37. A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer.
Choudhuri S; Sharma C; Banerjee A; Kumar S; Kumar L; Singh N
Mol Cell Biochem; 2014 Jan; 386(1-2):259-69. PubMed ID: 24141793
[TBL] [Abstract][Full Text] [Related]
38. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
39. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
Zou L; He X; Zhang JW
Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
